Study S001434

Gastric Fundal Mucosal Ablation for Weight Management in Patients Stopping Glucagon-like Peptide-1 Receptor Agonists

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06734312
Acronym: MAINTAIN
Study type: INTERVENTIONAL
Masking: NONE
Status: RECRUITING
Enrollment: 20
Start: 2025-01-01
Primary completion: 2026-06
Lead sponsor: Dr. Christopher McGowan
Conditions: Obesity and Obesity-related Medical Conditions; Obesity and Overweight; Obesity Prevention; Obesity Recidivism; GLP-1; Ablation Techniques
Interventions: DEVICE:Gastric Fundal Mucosal Ablation (GFMA)
Results posted: FALSE
Individual participant data sharing: UNDECIDED

Registered primary outcomes

Percent Change in Total Body Weight Loss (TBWL) from Baseline [12 months]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0017063	Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials. Popoviciu MS, International journal of molecular sciences	2023	Randomized trial	PMID 37445623 DOI	registry reference BACKGROUND:37445623
R0022757	Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Wilding JPH, Diabetes, obesity & metabolism	2022	Randomized trial	PMID 35441470 DOI	registry reference BACKGROUND:35441470